Cidara Therapeutics (CDTX) Competitors $105.62 -5.02 (-4.54%) Closing price 04:00 PM EasternExtended Trading$106.94 +1.32 (+1.25%) As of 07:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock CDTX vs. ELAN, BBIO, VRNA, RVMD, MRUS, RNA, GRFS, CYTK, RYTM, and ABVXShould you be buying Cidara Therapeutics stock or one of its competitors? The main competitors of Cidara Therapeutics include Elanco Animal Health (ELAN), BridgeBio Pharma (BBIO), Verona Pharma PLC American Depositary Share (VRNA), Revolution Medicines (RVMD), Merus (MRUS), Avidity Biosciences (RNA), Grifols (GRFS), Cytokinetics (CYTK), Rhythm Pharmaceuticals (RYTM), and Abivax (ABVX). These companies are all part of the "pharmaceutical products" industry. Cidara Therapeutics vs. Its Competitors Elanco Animal Health BridgeBio Pharma Verona Pharma PLC American Depositary Share Revolution Medicines Merus Avidity Biosciences Grifols Cytokinetics Rhythm Pharmaceuticals Abivax Cidara Therapeutics (NASDAQ:CDTX) and Elanco Animal Health (NYSE:ELAN) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, institutional ownership, media sentiment, valuation, dividends, earnings and profitability. Which has preferable earnings and valuation, CDTX or ELAN? Elanco Animal Health has higher revenue and earnings than Cidara Therapeutics. Cidara Therapeutics is trading at a lower price-to-earnings ratio than Elanco Animal Health, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCidara TherapeuticsN/AN/A-$169.83M-$11.13-9.49Elanco Animal Health$4.44B2.30$338M$0.8623.85 Which has more risk & volatility, CDTX or ELAN? Cidara Therapeutics has a beta of 1.33, meaning that its stock price is 33% more volatile than the S&P 500. Comparatively, Elanco Animal Health has a beta of 1.65, meaning that its stock price is 65% more volatile than the S&P 500. Is CDTX or ELAN more profitable? Elanco Animal Health has a net margin of 9.68% compared to Cidara Therapeutics' net margin of 0.00%. Elanco Animal Health's return on equity of 7.04% beat Cidara Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Cidara TherapeuticsN/A -50.81% -42.46% Elanco Animal Health 9.68%7.04%3.45% Do analysts recommend CDTX or ELAN? Cidara Therapeutics presently has a consensus price target of $146.50, suggesting a potential upside of 38.70%. Elanco Animal Health has a consensus price target of $19.14, suggesting a potential downside of 6.69%. Given Cidara Therapeutics' higher possible upside, analysts clearly believe Cidara Therapeutics is more favorable than Elanco Animal Health.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cidara Therapeutics 1 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 2.91Elanco Animal Health 0 Sell rating(s) 3 Hold rating(s) 6 Buy rating(s) 2 Strong Buy rating(s) 2.91 Does the media favor CDTX or ELAN? In the previous week, Cidara Therapeutics had 9 more articles in the media than Elanco Animal Health. MarketBeat recorded 20 mentions for Cidara Therapeutics and 11 mentions for Elanco Animal Health. Elanco Animal Health's average media sentiment score of 0.61 beat Cidara Therapeutics' score of 0.49 indicating that Elanco Animal Health is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cidara Therapeutics 3 Very Positive mention(s) 3 Positive mention(s) 7 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral Elanco Animal Health 4 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals & insiders have more ownership in CDTX or ELAN? 35.8% of Cidara Therapeutics shares are held by institutional investors. Comparatively, 97.5% of Elanco Animal Health shares are held by institutional investors. 3.9% of Cidara Therapeutics shares are held by insiders. Comparatively, 0.9% of Elanco Animal Health shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. SummaryElanco Animal Health beats Cidara Therapeutics on 11 of the 15 factors compared between the two stocks. Get Cidara Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CDTX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CDTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CDTX vs. The Competition Export to ExcelMetricCidara TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.81B$3.37B$6.11B$10.46BDividend YieldN/A2.29%5.73%4.77%P/E Ratio-9.4922.7785.3627.36Price / SalesN/A485.21607.16135.99Price / CashN/A46.7037.4661.86Price / Book7.0810.5512.426.81Net Income-$169.83M-$52.58M$3.32B$276.80M7 Day Performance7.22%1.09%1.01%0.27%1 Month Performance57.85%16.09%10.75%8.31%1 Year Performance938.54%18.41%76.20%35.60% Cidara Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CDTXCidara Therapeutics4.0806 of 5 stars$105.62-4.5%$146.50+38.7%+974.2%$2.81BN/A-9.4990ELANElanco Animal Health2.7881 of 5 stars$20.68+0.2%$18.33-11.3%+41.0%$10.25B$4.44B24.059,000Analyst RevisionBBIOBridgeBio Pharma4.2213 of 5 stars$54.61+3.3%$63.94+17.1%+119.2%$10.11B$221.90M-13.35400VRNAVerona Pharma PLC American Depositary Share1.4526 of 5 stars$106.91+0.1%$109.00+2.0%N/A$9.20B$42.28M-107.9930Positive NewsRVMDRevolution Medicines4.1276 of 5 stars$46.58-0.3%$74.64+60.2%-3.5%$8.73B$11.58M-10.35250Analyst ForecastInsider TradeMRUSMerus0.889 of 5 stars$94.270.0%$93.12-1.2%+81.8%$7.13B$56.23M-17.1437RNAAvidity Biosciences2.0042 of 5 stars$46.18-1.7%$68.32+47.9%+3.0%$6.86B$10.90M-12.97190GRFSGrifols3.7642 of 5 stars$9.61-3.4%$10.30+7.2%+11.7%$6.84B$7.81B8.2123,822Positive NewsCYTKCytokinetics3.5724 of 5 stars$60.64+6.4%$76.64+26.4%+12.0%$6.82B$18.47M-11.89250RYTMRhythm Pharmaceuticals3.0481 of 5 stars$97.86-1.2%$106.64+9.0%+109.4%$6.58B$130.13M-32.51140ABVXAbivax2.8443 of 5 stars$86.67+3.3%$103.29+19.2%+925.4%$6.34BN/A0.0061Analyst ForecastHigh Trading Volume Related Companies and Tools Related Companies Elanco Animal Health Competitors BridgeBio Pharma Competitors Verona Pharma PLC American Depositary Share Competitors Revolution Medicines Competitors Merus Competitors Avidity Biosciences Competitors Grifols Competitors Cytokinetics Competitors Rhythm Pharmaceuticals Competitors Abivax Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CDTX) was last updated on 10/15/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredArizona-made nanochips the new millionaire maker?George Gilder handed President Reagan the first microchip that helped create $6.5 trillion in wealth over the ...Banyan Hill Publishing | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cidara Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cidara Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
